AetherAI, an AI-driven medical company backed by Quanta Computer, Cathay Financial Group, and CDIB Capital, is set to list on the emerging stock market on October 26 at NT$32 per share. Chairman and CEO Joe Chao-Yuan Yehannounced on October 25 that the company has secured partnerships with over 10 medical centers and general hospitals in Taiwan and has also received international orders from hospitals in Japan and Germany. Notably, AetherAI recently landed a major contract with Frankfurt University Hospital, which is expected to significantly boost revenue over the next six months.
Founded in October 2015 by Dr. Yeh, AetherAI currently has a paid-in capital of NT$880 million. A graduate of National Taiwan University’s College of Medicine, Dr. Yeh discovered a passion for programming and image analysis while pursuing a Ph.D. in pathology at the University of Southern California. This led him to develop expertise in artificial intelligence (AI) and focus on digitizing pathology. Combining biotechnology (BIO) with information and communication technology (ICT), AetherAI launched its first product, the aetherSlide Digital Pathology System, in 2019, which was adopted by Chang Gung Memorial Hospital.
Since 2019, AetherAI has attracted investments from leading institutional investors, including Cathay Venture Capital, Quanta Computer, Ono Pharmaceutical, TBB Venture Capital, Cathay General Hospital, and CDIB Capital. In its latest funding round, the company raised NT$765 million, with continued support from major investors like Quanta Computer (holding a 15% stake), Cathay General Hospital and Cathay Venture Capital (11.12% combined), and CDIB Capital and CSC Venture Capital (3% each).
AetherAI’s key offerings include:
These solutions are designed for the detection of various cancers, including gastric, lung, blood, and colorectal cancers. The company has obtained multiple domestic and international certifications for its products. In the first half of 2024, AetherAI reported consolidated revenue of NT$43.36 million, a year-on-year growth of 71.2%, but posted a net loss of NT$1.11 per share.
Dr. Yeh explained that AetherAI employs a consultative sales approach with hospitals and anticipates significant revenue growth from collaborations with domestic and international medical institutions in the coming months. Overseas sales are expected to account for over 50% of the company’s revenue this year, with more than half generated through partnerships with Quanta’s hardware solutions. Current clients include leading hospitals in Taiwan such as NTU Hospital, Chang Gung Memorial Hospital, Taipei Veterans General Hospital, Cathay General Hospital, Mackay Memorial Hospital, Chung Shan Medical University Hospital, Changhua Christian Hospital, and Tungs' Taichung Metroharbor Hospital, as well as renowned international institutions like Tübingen University Hospital and Frankfurt University Hospital in Germany.
According to a report by Persistence Market Research, the global digital pathology market is projected to grow from USD 8.1 billion in 2024 to USD 19.5 billion by 2031, with a compound annual growth rate (CAGR) of 13.5%. As cancer incidence rises and the demand for precision medicine increases, digital pathology solutions are becoming a core driver in global healthcare systems. In North America, the U.S. FDA has classified digital pathology as a Class II medical device, signaling significant growth potential.
Dr. Yeh emphasized that AetherAI will continue to deepen its expertise in medical imaging AI, expand its footprint in Europe, the U.S., and Asia, and conduct multi-center clinical trials to solidify its technological edge with robust medical evidence. The company also aims to enhance international collaboration, particularly in cancer diagnosis and treatment, and launch highly accurate AI diagnostic solutions.
Additionally, AetherAI is actively developing next-generation technologies, such as its proprietary Gigapixel high-resolution AI training methodology and cutting-edge foundation AI models. These innovations aim to improve AI training efficiency and reduce dependency on training data, enabling more diverse AI-assisted diagnostic applications. By accelerating AI integration into clinical practice, AetherAI seeks to advance early cancer screening and precision medicine.
Resource: 大股東助攻！廣達轉投資AI醫療公司雲象科技將登興櫃
